Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 29, 2018 03:14 ET | Source: Esperite N.V.

Esperite (ESP), The Cell Factory presents pre-clinical results on the new products of the 2nd generation EV's drugs for treatment of inflammatory diseases

Esperite with its biotech company The Cell Factory has acquired from OPBG the full rights to the IP and the international patent family covering the invention and the therapeutic use of the EV's...
March 27, 2018 08:00 ET | Source: RedHill Biopharma Ltd.

RedHill Biopharma Announces Two Oral Presentations on BEKINDA® 24 mg for acute gastroenteritis at the SAEM 2018 Annual Meeting

TEL-AVIV, Israel and RALEIGH, N.C., March 27, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (Tel-Aviv Stock Exchange:RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical...
March 26, 2018 09:35 ET | Source: Immune Therapeutics, Inc.

Immune Therapeutics, Inc. Received Minutes From FDA Meeting for Lodonal™ for the Treatment for Crohn’s Disease

ORLANDO, Fla., March 26, 2018 (GLOBE NEWSWIRE) -- via OTC PR WIRE-- Immune Therapeutics, Inc. (OTCQB:IMUN) ("Immune" "IMUN" or the "Company"), a clinical late stage biopharmaceutical company focused...
March 26, 2018 08:00 ET | Source: RedHill Biopharma Ltd.

RedHill Biopharma Announces DDW 2018 Poster of Distinction on Positive Phase II Results with BEKINDA® for IBS-D

TEL-AVIV, Israel and RALEIGH, N.C., March 26, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (Tel-Aviv Stock Exchange:RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical...
March 23, 2018 13:00 ET | Source: TiGenix

TiGenix et Takeda annoncent l'autorisation d'Alofisel® (darvadstrocel) pour le traitement des fistules périanales complexes dans la maladie de Crohn en Europe

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} COMMUNIQUÉ DE PRESSE INFORMATIONS...
March 23, 2018 13:00 ET | Source: TiGenix

TiGenix en Takeda kondigen aan dat Alofisel® (darvadstrocel) de goedkeuring krijgt voor de behandeling in Europa van complexe perianale fistels bij de ziekte van Crohn

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} PERSBERICHT GEREGLEMENTEERDE...
March 23, 2018 13:00 ET | Source: TiGenix

TiGenix and Takeda announce Alofisel® (darvadstrocel) receives approval to treat complex perianal fistulas in Crohn's disease in Europe

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} PRESS RELEASE REGULATED INFORMATION...
March 20, 2018 08:00 ET | Source: RedHill Biopharma Ltd.

RedHill Biopharma to Present at H.C. Wainwright Annual Global Life Sciences Conference

TEL-AVIV, Israel and RALEIGH, N.C., March 20, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (Tel-Aviv Stock Exchange:RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical...
March 19, 2018 07:00 ET | Source: RedHill Biopharma Ltd.

RedHill Biopharma Announces Poster Presentation on New Potential Therapeutic Applications of RHB-107 at the AACR 2018 Annual Meeting

Data from non-clinical studies indicated that WX-UK1, the active metabolite of RHB-107 (formerly MESUPRON), is a potent and specific inhibitor of five human serine proteases, suggesting new potential...
March 16, 2018 06:30 ET | Source: Research and Markets

Tumor Necrosis Factor Inhibitors Drug Market, 2024

Dublin, March 16, 2018 (GLOBE NEWSWIRE) -- The "Global Tumor Necrosis Factor Inhibitors Drug Market, Dosage, Price & Clinical Pipeline Outlook 2024" report has been added to ...